source: Wikipedia

For a brief moment, the KRAS field appeared to be settling into something familiar. The target had yielded, development paths were becoming clearer, and the next phase looked like one of execution rather than exploration. Sound familiar?

Recent signals, however, suggest this sense of stability may have been premature. Across programmes, the data are beginning to rhyme in unexpected ways with responses behaving oddly, dependencies surfacing only transiently, and therapeutic pressure provoking adaptation rather than resolution.

Taken together, these undercurrents suggest a deeper shift is coming into focus.

The challenge no longer sits neatly at the level of a single node or pathway, but somewhere more elusive where tumours adjust their internal wiring, occupy altered states, and exploit biology visible only under stress.

This was not the future most people imagined for KRAS just a few years ago, yet it is increasingly the one the field must now confront.  In our latest Preview we discuss these changes and future directions to watch out for…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers